Interview with Keith Martin, CEO, Apitope
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
Address: Bristol & Bath Science Park
Dirac Crescent
Emersons Green
Bristol
BS16 7FR
United Kingdom
Tel: +44 (0)117 370 7720
Apitope is a privately owned European biotech company developing antigen specific therapeutic peptides for the treatment of allergy and autoimmune diseases, including multiple sclerosis, Graves’ disease, Uveitis, and others.
Autoimmune disease arises from our own immune system responding incorrectly to the proteins and complex tissues that make up our body. For example, multiple sclerosis is caused by immune cells attacking the myelin sheath that insulates the neurons within nervous system including the brain and spinal cord.
Our research team is currently developing peptide based therapeutics designed to selectively suppress this aberrant interaction between immune cell and protein antigen, reinstating the body’s natural immune tolerance to the body’s own proteins.
This approach is founded on peer reviewed research demonstrating that treatment with a soluble, synthetic peptide derived from a known antigenic protein (such as myelin basic protein; a constituent of myelin) can prevent the immune system from responding to that protein as a threat.
In order to induce this process of immune-tolerance we must first identify the region within an antigen that the immune system recognises as a threat during an autoimmune disease. This region is referred to as an epitope.
However, Apitope has shown that in order for an epitope to effectively suppress disease it must behave as an Apitope® – Antigen Processing Independent epiTOPE. Our patented discovery platform enables us to efficiently identify and design these unique peptide therapeutics.
We aim to become the partner of choice for companies developing disease modifying therapies for autoimmune diseases and allergies.
Driving us towards this goal, Apitope has an highly experienced senior management team, each with a proven track record in the translation of novel therapeutics from bench to bedside.
Apitope’s most advanced product candidate, ATX-MS-1467, is undergoing Phase I trials in patients with multiple sclerosis. Our clinical development team is working in partnership with Merck-Serono, a leading company in the development and marketing of MS therapies, to move our product ahead as quickly and effectively as possible.
The company’s lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association…
After a tumultuous year, AstraZeneca is creating a standalone vaccine unit and will begin to charge for its COVID-19 vaccine shot, having previously provided it at cost. PharmaBoardroom looks back…
The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over…
Cyril Titeux, senior VP mid-sized markets EMEA & strategic leader at Janssen, argues that the current focus of many health systems on efficiency, streamlining, and reducing spending is leaving them…
British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again finding itself under the spotlight as analysts and shareholders alike continue to query the…
Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the International Society of Paediatric Oncology (SIOP) discusses the latest advancements in childhood cancer treatment, the…
Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient and patient organizations’ involvement in the decision-making process for therapy appraisals, the use of HTA,…
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of…
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest acquisition; and calls for a national registry to…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on NASDAQ, raising over USD 30 million. Founded…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left…
See our Cookie Privacy Policy Here
